Theravance Biopharma (TBPH) Assets Average (2014 - 2026)

Theravance Biopharma (TBPH) has 13 years of Assets Average data on file, last reported at $478.9 million in Q1 2026.

• On a quarterly basis, Assets Average rose 37.28% year-over-year to $478.9 million in Q1 2026; TTM through Mar 2026 was $478.9 million, a 37.28% increase from a year earlier, with the FY2025 full-year figure at $419.9 million, up 14.07% from the prior year.
• Assets Average for Q1 2026 stood at $478.9 million, up from $450.5 million in the prior quarter.
• Over the last five years, Assets Average for TBPH reached as high as $685.4 million in Q4 2022 and fell as low as $348.9 million in Q1 2025.
• Historically, Assets Average has averaged $435.6 million across 5 years, with a median of $397.8 million in 2023.
• Across the five-year window, Assets Average surged 76.22% in 2022 and slumped 41.97% in 2023, its largest moves.
• Year by year, Assets Average stood at $685.4 million in 2022, then sank by 41.97% to $397.8 million in 2023, then declined by 10.72% to $355.1 million in 2024, then grew by 26.86% to $450.5 million in 2025, then climbed by 6.31% to $478.9 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $478.9 million in Q1 2026, $450.5 million in Q4 2025, and $420.7 million in Q3 2025.